Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01103375 · ClinicalTrials.gov registry record · Phase 1
Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma
A Phase 1 study, sponsored by Wake Forest University Health Sciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT01103375 is a Phase 1 study that was terminated before completion, run by Wake Forest University Health Sciences. The registered enrollment target is 5 participants.
The verdict
NCT01103375, a Phase 1 study, was terminated before completion, sponsored by Wake Forest University Health Sciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This phase I trial is studying the side effects and best dose of erlotinib hydrochloride when given with isotretinoin in treating patients with recurrent malignant glioma. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Isotretinoin may help cells that are involved in the body's immune response to work better. Giving erlotinib hydrochloride together with isotretinoin may kill more tumor cells
Interventions
- GENETIC protein expression analysis
- OTHER laboratory biomarker analysis
- DRUG erlotinib hydrochloride
- DRUG isotretinoin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2010-05 |
| Est. Completion | 2013-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01103375
The ClinicalTrials.gov registry entry for NCT01103375 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which protein expression analysis is the first listed.
NCT01103375 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01103375 about?
NCT01103375 is a clinical study titled "Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma". This phase I trial is studying the side effects and best dose of erlotinib hydrochloride when given with isotretinoin in treating patients with recurrent malignant glioma. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Isotretinoin ...
What is the current status of trial NCT01103375?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2010-05. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01103375?
The interventions under investigation include: protein expression analysis (GENETIC), laboratory biomarker analysis (OTHER), erlotinib hydrochloride (DRUG), isotretinoin (DRUG).
Who is sponsoring clinical trial NCT01103375?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.